Isomorphic Labs’ $2.1B Series B: AI Drug Design Gets Sovereign-Scale Capital

AI drug-design stories often stop at structure prediction. A $2.1B round with sovereign and hyperscaler capital is a bet that IsoDDE can compress the path toward clinical candidates — financing conviction ahead of clinical proof.

Isomorphic Labs (May 12), the AI-first drug design company spun out of Google DeepMind, announced a $2.1 billion Series B led by Thrive Capital, with Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. Proceeds: scale the IsoDDE platform, expand global operations (London, Cambridge, and other hubs), and advance therapeutic candidates toward clinical trials across modalities.

Round and platform

• Amount: $2.1B Series B.
• Lead: Thrive Capital; participants include Alphabet, GV (existing), MGX, Temasek, CapitalG, UK Sovereign AI Fund (new).
• Tech: IsoDDE — unified AI system for biomolecular structures, binding affinities, and novel candidates (small molecules, biologics, antibodies); builds on AlphaFold-lineage work.
• Pipeline focus: Oncology and immunology among internal areas; biopharma partnerships cited.

Leadership quotes (Hassabis; Ruth Porat) frame confidence in AI-first healthcare timelines — company and investor statements.

Claims vs checks

Round size and investor list are Isomorphic Labs primary (PR Newswire; Bloomberg / Fierce Biotech confirmation). Clinical acceleration claims are aspirational until trial readouts. Prior ~$600M external round context is company history, not this round’s diligence package.

Limits

• Capital ≠ approved drugs.
• IsoDDE performance vs traditional discovery timelines is not independently audited in the raise announcement.
• Sovereign fund participation is strategic interest, not regulatory endorsement.

Sources

• Isomorphic Labs Series B announcement (May 12, 2026).
• PR Newswire (May 12, 2026).
• Bloomberg and Fierce Biotech coverage (May 12, 2026).